Veronique Beiss

Veronique Beiss

Auto-generated profile, based on publicly available information

Veronique Beiss

Department of NanoEngineering, University of California-San Diego, La Jolla, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
MSMatthew D. Shin
Matthew D. Shin
SSSourabh Shukla
Sourabh Shukla
YCYoung Hun Chung
Young Hun Chung
VBVeronique Beiss
Veronique Beiss
SCSoo Khim Chan
Soo Khim Chan
NSNicole Steinmetz
Nicole Steinmetz

1 November 2019 in Journal of Virology
Verified
Journal Article
Closed access
CWChao Wang
Chao Wang
VBVeronique Beiss
Veronique Beiss
NSNicole Steinmetz
Nicole Steinmetz
The engagement of antiviral effector responses caused by viral infection is essential when using viruses or virus-like particles (VLPs) as an immunotherapeutic agent. Here, we compare the chemophysical and immunostimulatory properties of wild-type cowpea mosaic virus (CPMV) (RNA containing) and eCPMV (RNA-free VLPs) produced from two expression systems (agrobacterium-based plant expression system and baculovirus-insect cell expression). CPMV and eCPMV could each be developed as novel adjuvants to overcome immunosuppression and thus promote tumor regression in ovarian cancer (and other tumor types). To our knowledge, this is the first study to define the immunotherapeutic differences between CPMV and eCPMV, which is essential for the further development of biomedical applications for plant viruses and the selection of rational combinations of immunomodulatory reagents.

25 May 2021 in Biomaterials
Verified
Journal Article
Closed access
CMChenkai Mao
Chenkai Mao
VBVeronique Beiss
Veronique Beiss
JFJennifer Fields
Jennifer Fields
NSNicole Steinmetz
Nicole Steinmetz
Steven N. FieringSteven N. Fiering
Steven N. Fiering

11 September 2020 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
SSSourabh Shukla
Sourabh Shukla
CWChao Wang
Chao Wang
VBVeronique Beiss
Veronique Beiss
HCHui Cai
Hui Cai
TWTorus Washington
Torus Washington
NSNicole Steinmetz
Nicole Steinmetz
The immunosuppressive tumor microenvironment enables cancer to resist immunotherapies. We have established that intratumoral administration of plant-derived Cowpea mosaic virus (CPMV) nanoparticles as an in situ vaccine overcomes the local immunosuppression and stimulates a potent anti-tumor response in several mouse cancer models and canine patients. CPMV does not infect mammalian cells but acts as a danger signal that leads to the recruitment and activation of innate and subsequently, adaptive immune cells. In the present study we addressed whether other icosahedral viruses or virus-like particles (VLPs) of plant, bacteriophage and mammalian origin can be similarly employed as intratumoral immunotherapy. Our results indicate that CPMV in situ vaccine outperforms Cowpea chlorotic mottle virus (CCMV), Physalis mosaic virus (PhMV), Sesbania mosaic virus (SeMV), bacteriophage Qβ VLPs, or Hepatitis B virus capsids (HBVc). Furthermore, ex vivo and in vitro assays reveal unique features of CPMV that makes it an inherently stronger immune stimulant.

10 April 2019 in Cancers
Verified
Journal Article
Open access
PDF file
AAmber kerstetter-fogle
Amber kerstetter-fogle
SSSourabh Shukla
Sourabh Shukla
CWChao Wang
Chao Wang
VBVeronique Beiss
Veronique Beiss
PHPeggy L. R. Harris
Peggy L. R. Harris
NSNicole Steinmetz
Nicole Steinmetz
Despite aggressive multi-modality treatment with surgery, radiation and chemotherapies, malignant glioma inevitably recurs and has dismal survival rates. Recent progress in immunotherapy has led to a resurgence of interest, and immunotherapies are being investigated for treatment of glioma. However, the unique brain anatomy and a highly immunosuppressive glioma microenvironment pose significant challenges to achieving efficacy. Thus, there is a critical need for assessment of next-generation immunotherapies for glioma. In this study, we have investigated the efficacy of the nanoparticle platform technology based on plant-derived Cowpea mosaic virus like particles (empty CPMV or eCPMV) to instigate a potent immune response against intracranial glioma. CPMV immunotherapy has been shown to efficiently reverse the immunosuppressive tumor microenvironments in pre-clinical murine models of dermal melanoma and metastatic melanoma, metastatic breast cancer, intraperitoneal ovarian cancer and in canine patients with oral melanoma. In the present study, we demonstrate that in situ administration of CPMV immunotherapy in the setting of glioma can effectively recruit unique subset of effector innate and adaptive immune cells to the brain parenchyma while reducing immune suppressive cellular population, leading to regression of intracranial glioma. The in situ CPMV nanoparticle vaccine offers a potent yet safe and localized immunotherapy for intracranial glioma.